Nektar Therapeutics reports results for the quarter ended June 30 - Earnings Summary

Nektar Therapeutics

08/08/2025 05:15

Nektar Therapeutics NKTR.OQ reported a quarterly adjusted loss of $2.95​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.75.  The mean expectation of eight analysts for the quarter was for a loss of $3.03 per share. Wall Street expected results to range from $-3.79 to $-2.19 per share.

Revenue fell 52.4% to $11.18 million from a year ago; analysts expected $10.85 million.

Nektar Therapeutics's reported EPS for the quarter was a loss of $2.95​.

The company reported a quarterly loss of $41.59 million.

Nektar Therapeutics shares had fallen by 13.1% this quarter and gained 60.9% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 4.3% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Nektar Therapeutics is $95.00, about 77.1% above its last closing price of $21.75

This summary was machine generated from LSEG data August 8 at 04:14 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-3.03
-2.95
Beat
Mar. 31 2025
-2.46
-3.60
Missed
Dec. 31 2024
-2.52
-2.40
Beat
Sep. 30 2024
-3.16
-2.70
Beat